NICE recommends 'breakthrough' therapy for blood cancer

The National Institute for Health and Care Excellence (NICE) has recommended a targeted therapy for blood cancer that offers “significant survival benefits” for some patients on the NHS in England. In draft guidance, published on 13 June 2025, NICE approved belantamab mafodotin (Blenrep; GSK), in combination with bortezomib (Velcade; Janssen-Cilag) and dexamethasone, as a second-line […]

Publication Details

Journal: Pharmaceutical journal/The pharmaceutical journal
Published: 2025-01-01
DOI: https://doi.org/10.1211/pj.2025.1.360642
Primary Topic: Cancer Genomics and Diagnostics
Type: article
Field-Weighted Citation Impact: 0.00

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

NICE recommends 'breakthrough' therapy for blood cancer

Jan 1, 2025

Pharmaceutical journal/The pharmaceutical journal

Cancer Genomics and Diagnostics

article

NICE recommends 'breakthrough' therapy for blood cancer

January 1, 2025article en

Abstract

Pharmaceutical journal/The pharmaceutical journal

Good health and well-being

Openalex Percentile: Top 82%

Cancer Genomics and Diagnostics

DOI Source OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

NICE recommends 'breakthrough' therapy for blood cancer · Pharmaceutical journal/The pharmaceutical journal (2025) | TGRS Research Map | TGRS